View More
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
Audio from Clinical Care Options: Zobair Younossi, MD, discusses the clinical impact of the most important NAFLD/NASH data from EASL 2019 in Vienna.
Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD
Released: May 2, 2019
April 10-14, 2019; Vienna, Austria: Expert faculty members summarize key viral hepatitis studies from this important annual conference.
Nancy Reau, MD
Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD
Stefan Zeuzem, MD
Released: April 30, 2019
Phase II safety and efficacy data with thyroid hormone receptor beta agonist VK2809 vs placebo in NAFLD, from EASL 2019, as reported by Clinical Care Options (CCO).
EASL 2019 downloadable slideset: Phase II efficacy and safety results of emricasan, an oral caspase inhibitor, in NASH cirrhosis and severe portal HTN as reported by Clinical Care Options (CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.
CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.